𝔖 Bobbio Scriptorium
✦   LIBER   ✦

In reference to Hereditary Hemorrhagic Telangiectasia/Avastin

✍ Scribed by Gregor Bachmann-Harildstad

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
39 KB
Volume
120
Category
Article
ISSN
0023-852X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Hereditary hemorrhagic telangiectasia/av
Hereditary hemorrhagic telangiectasia/avastin
✍ Terence M. Davidson; Scott E. Olitsky; Julie L. Wei πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 389 KB

## Abstract This is the first scientific report of hereditary hemorrhagic telangiectasia (HHT) epistaxis treatment by intranasal spraying of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin). Epistaxis in patients with HHT is a morbid, mortal condition that is difficult

The effect of bevacizumab (Avastin) trea
The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia
✍ Jana Simonds; Frank Miller; Jess Mandel; Terence M. Davidson πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 83 KB

## Abstract ## Objectives/Hypothesis: Determine the effectiveness of treating epistaxis in hereditary hemorrhagic telangiectasia (HHT) with potassium titanyl phosphate (KTP) laser cautery combined with submucosal injection of 100 mg of bevacizumab. ## Study Design: Retrospective pilot study. ##

Safety of intranasal Bevacizumab (avasti
Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis
✍ Sonia Chen IV; Tom Karnezis; Terence M. Davidson πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 73 KB

## Abstract ## Objectives/Hypothesis: Assess for complications of intranasal Bevacizumab application in patients with hereditary hemorrhagic telangiectasia (HHT)‐associated epistaxis. ## Study Design: Retrospective chart review. ## Methods: In 58 patients presenting with recurrent HHT epistaxi

Efficacy of intranasal bevacizumab (Avas
Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis
✍ Tom T. Karnezis; Terence M. Davidson πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 78 KB

## Abstract ## Objectives/ Hypothesis: Intranasal Bevacizumab is an effective therapy for epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). ## Study Design: Retrospective chart review. ## Methods: In 32 successive patients presenting with recurrent HHT epistaxis 25–100 mg